Sci Rep 14 , 14403 (2024)
But not everyone experiences the same dramatic effects

Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself

These actions are likely due to the potential of BPC-157 to simulate vasodilatation and angiogenesis (new blood vessel formation) due to its action on peptidergic growth factors such as endothelial growth factor, Consequently, the peptide has demonstrated significant protective effects against gastric mucosal injury in rat models
PMID: 16352683 Khorram O, Laughlin GA, Yen SS